Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group obtained investigational new drug approval for TQB6426 from the U.S. Food and Drug Administration.
The drug is intended for advanced malignant tumors, according to a Thursday Hong Kong bourse filing.